SpinalCyte, a Texas-based tissue engineering technology company focused on regrowth of the spinal disc nucleus using human dermal fibroblasts, has been issued a new Japanese patent.
The technology described in the patent (No. 6151006, “Methods And Compositions For Repair Of Cartilage Using An In Vivo Bioreactor” involves preparing a cell/scaffold composition wherein the cells are chondrocytes or chondrocyte-like cells. The patent calls for applying human dermal fibroblasts (HDFs) to the scaffold and subjecting the fibroblasts to mechanical stress, hypoxia and intermittent hydrostatic pressure. Further, the technology described uses a bone morphogenetic growth factor.
With this addition, SpinalCyte’s portfolio now includes 23 US and foreign patents issued and directly owned by the company, along with 46 patents pending.
